Drug intelligence / Profile preview

valproate bismuth

Development stage
Unknown
Lead developer
MINAKEM
Modality
Small Molecules
Administration
Oral, Sublingual
01

Overview

**Valproate bismuth** is a discrete bismuth(III) salt of valproic acid, consisting of one bismuth cation coordinated with three valproate anions. It is also called **bismuth dipropylacetate** and is the medicinal ingredient in the Canadian non-prescription rectal suppository **Neo-Laryngobis**. Neo-Laryngobis contains 135 mg bismuth dipropylacetate per suppository and is marketed for symptomatic relief associated with pharyngitis, laryngitis, tonsillitis, sore throat, and loss of voice. Its product-specific pharmacological target and mechanism in throat disorders are not established in the identified sources; the well-known central nervous system actions of valproic acid should not be assumed to describe this bismuth-valproate salt or its local throat indication. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Valproate-bismuth))

Brand names
Neo-Laryngobis
Other names
bismuth (3+) tris (2-propylpentanoate)bismuth (3+) tris (2-propylvalerate)bismuth 2-propylpentanoatebismuth2-propylpentanoatebismuth-2-propylpentanoatebismuth 2-propylvaleratebismuth2-propylvaleratebismuth-2-propylvaleratebismuth dipropylacetatebismuth trivalproate
02

Targets

KCNH2 (Voltage-gated potassium channel subfamily H member 2)SSADH (Succinate-semialdehyde dehydrogenase)CYP3A4 (Cytochrome P450 3A4)ABAT (4-aminobutyrate aminotransferase)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on valproate bismuth.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on valproate bismuth.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call